Adjuvant therapy (AT) with raltitrexed (RAL) in colorectal cancer (CRC) patients (pts) intolerant of 5-fluorouracil (5FU).

被引：0
|
作者：
Wilson, K. S.
Barnett, J. B.
Gill, S.
Khoo, K. E.
Fitzgerald, C. A.
机构：
[1] British Columbia Canc Agcy, Victoria, BC, Canada
[2] British Columbia Canc Agcy, Kelowna, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3571
引用
收藏
页码：163S / 163S
页数：1
相关论文
共 50 条
  • [21] INFLUENCE OF AGE ON PHARMACOKINETICS OF 5-FLUOROURACIL (5FU)
    SCHILCHER, RB
    DECKER, DA
    EVANS, LJ
    MARTINO, S
    KRESGE, C
    YOUNG, JD
    SAMAL, BA
    SINGHAKOWINTA, A
    BREAST CANCER RESEARCH AND TREATMENT, 1984, 4 (04) : 347 - 347
  • [22] INTERACTION OF MEROMELIA GENE AND 5-FLUOROURACIL (5FU)
    IGARASHI, E
    YASUDA, M
    TERATOLOGY, 1988, 38 (05) : 533 - 534
  • [23] THE INFLUENCE OF CIMETIDINE ON THE PHARMACOKINETICS OF 5-FLUOROURACIL (5FU)
    HARVEY, VJ
    SLEVIN, ML
    DILLOWAY, M
    CLARK, PI
    JOHNSTON, A
    LANT, AF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 362 - 362
  • [24] Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/Oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000-05 trial
    Boige, V.
    Castaing, M.
    Loriot, M. A.
    Barrois, M.
    Miran, I.
    Mulot, C.
    Pignon, J. R.
    Ducreux, M.
    Laurent-Puig, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 240 - 241
  • [25] Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000-05 trial
    Castaing, M., Jr.
    Loriot, M. A.
    Barrois, M.
    Miran, I.
    Mulot, C.
    Laurent-Puig, P.
    Pignon, J. P.
    Ducreux, M.
    Boige, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] MBD4 Frameshift Mutation Changes 5-Fluorouracil (5FU) Sensitivity in Colorectal Cancer
    Iwaizumi, Moriya
    Suzuki, Satoshi
    Kanaoka, Shigeru
    Sugimoto, Ken
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (09) : 2436 - 2437
  • [27] ENZYMATIC CHANGES INDUCED BY THYMIDINE (TDR) AND 5-FLUOROURACIL (5FU) THERAPY
    SALSER, JS
    MARTIN, DS
    BALIS, ME
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 80 - 80
  • [28] MBD4 Frameshift Mutation Enhances 5-Fluorouracil (5FU) Sensitivity in Colorectal Cancer
    Iwaizumi, Moriya
    Martin, Paul
    Tseng-Rogenski, Stephanie
    Kanaoka, Shigeru
    Carethers, John M.
    GASTROENTEROLOGY, 2013, 144 (05) : S876 - S876
  • [29] Pharmacokinetic (PK) guided optimization of 5-fluorouracil (5-FU) dosing in the treatment of patients with colorectal cancer (CRC)
    Goal, Gaurav
    Chu, Edward
    Sun, Min
    Meisner, Dennis James
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] CHEMOTHERAPY OF ADVANCED COLORECTAL-CANCER AND OTHER MALIGNANCIES WITH 5-FLUOROURACIL (5FU) AND ANGUIDINE (ANG)
    MURPHY, WK
    VALDIVIESO, M
    BURGESS, MA
    BODEY, GP
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 419 - 419
12345